Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration
PD-1 inhibitors based therapeutic strategy may be a reasonable option in second-line setting for MGC who progressed on prior immunotherapy. Further larger prospective trials are warranted to validate these findings.
Authors
- Long Bai (ORCID: https://orcid.org/0000-0001-6111-5061)
- Qi Meng (ORCID: https://orcid.org/0000-0003-0738-2454)
- Dongsheng Zhang (ORCID: https://orcid.org/0000-0001-9097-0956)
- Jianwen Chen (ORCID: https://orcid.org/0000-0003-1904-2676)
- Yun‐Xin Lu
- Mengwei Zhang
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1186/s12885-025-14286-7
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province